MaxCyte Bolsters Leadership Team with Promotion of Brad Calvin to Chief Commercial Officer and New Key VP Appointments
GAITHERSBURG, Md., Oct. 13, 2020 /PRNewswire/ — MaxCyte, Inc., a global cell-based therapies and life sciences company, announces today a senior leadership promotion and appointments for two key vice president roles.
Brad Calvin has been promoted to Chief Commercial Officer. In his previous role as MaxCyte Executive Vice President, Global Commercial Operations, Mr. Calvin was responsible for leading the Company’s sales, marketing and business development functions to define product strategy, deliver new products and drive growth of its drug discovery and cell therapy businesses. In addition, Sarah Haecker Meeks, PhD, has joined the Company as Vice President, Business Development, and Steve Nardi has joined as Vice President, Manufacturing and Engineering Operations.
MaxCyte’s President & CEO Doug Doerfler, said: “Brad’s promotion is well-earned and important for MaxCyte’s future growth. Since joining MaxCyte in 2017, he has forged pivotal relationships with leading cell therapy and gene editing companies, leading